Evidence-Based Answers

Evidence Central™ is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research.


Instant Savings

Evidence Central iOS iPhone iPad Android

Available on your mobile device and the web, locate answers at the bedside or anywhere they’re needed. Save 10% Today

Word of the Day

IFOBTs moderately sensitive and highly specific for colon cancer

Clinical Question:
Are immunochemical fecal occult blood tests sensitive and specific enough to be used for colorectal cancer screening?

Bottom Line:
Immunochemical fecal occult blood tests (IFOBTs), such as OC-Micro, OC-Sensor, or OC-Light, are moderately sensitive (73% - 89%) and highly specific (92% - 95%) for identifying colorectal cancer. In comparison, Homoccult Sensa has a lower sensitivity (64% - 80%) and specificity (87% - 90%). IFOBTs also have the advantage of requiring only one sample. (LOE = 1c)

Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med 2014;160(3):171-181.  [PMID:24658694]

Study Design:
Meta-analysis (other)


Various (meta-analysis)

These researchers searched 5 databases and the reference lists of included studies, finding 19 eligible studies that evaluated the diagnostic accuracy of IFOBTs. Two authors used the STARD and PRISMA protocols and independently determined study eligibility, extracted the data, and evaluated study quality. They included cohort studies and randomized studies that used colonoscopy or longitudinal follow-up as the gold standard and only included studies published in English. They excluded studies or results that evaluated only the detection of adenomas. Limiting analysis to only currently available IFOBTs found a sensitivity of 82% (95% CI, 73% - 89%) and a specificity of 94% (92% - 95%). These numbers translate into a positive likelihood ratio of 13.10 and a negative likelihood ratio of 0.19. There was no difference in performance among different commercial products, and multiple sampling was no more accurate than a single sample. Heterogeneity among the studies was acceptable when removing products that are not commercially available. There was some evidence of publication bias. There are no head-to-head studies comparing one type of test with another, and no research evaluating the effectiveness of IFOBT testing on cancer-related mortality or all-cause mortality.


Site Licenses

Site license

Site Licenses are available for schools, universities, hospitals, government agencies, and companies. For more information, contact us.